Budesonide and Formoterol and Wakix Tablets
Determining the interaction of Budesonide and Formoterol and Wakix Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Concomitant use of pitolisant with NSAIDs and/or corticosteroids may increase the risk of gastrointestinal adverse effects such as dyspepsia, abdominal pain or discomfort, and gastritis due to potential additive irritant effects on the gastrointestinal mucosa. Clinical studies with pitolisant reported gastric disorders caused by hyperacidity in 3.5% of patients. However, the effects were described as mostly mild to moderate in severity. Data are not available on the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation. MANAGEMENT: Caution is advised if pitolisant is used in combination with NSAIDs and/or corticosteroids, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly or debilitated patients. If concomitant therapy is required, patients should be advised to report signs and symptoms of adverse GI effects, including abdominal pain or discomfort, dyspepsia, gastroesophageal reflux disease, gastritis, or the appearance of black, tarry stools. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Professional:MONITOR: Concomitant use of pitolisant with NSAIDs and/or corticosteroids may increase the risk of gastrointestinal adverse effects such as dyspepsia, abdominal pain or discomfort, and gastritis due to potential additive irritant effects on the gastrointestinal mucosa. Clinical studies with pitolisant reported gastric disorders caused by hyperacidity in 3.5% of patients. However, the effects were described as mostly mild to moderate in severity. Data are not available on the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.
MANAGEMENT: Caution is advised if pitolisant is used in combination with NSAIDs and/or corticosteroids, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly or debilitated patients. If concomitant therapy is required, patients should be advised to report signs and symptoms of adverse GI effects, including abdominal pain or discomfort, dyspepsia, gastroesophageal reflux disease, gastritis, or the appearance of black, tarry stools.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: budesonide / formoterol
Brand name: Symbicort, Symbicort Turbuhaler, Symbicort 400/12 Turbohaler
Synonyms: Budesonide and formoterol (inhalation)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Budesonide and Formoterol-Wal-Fex
- Budesonide and Formoterol-Wal-finate
- Budesonide and Formoterol-Wal-itin
- Budesonide and Formoterol-Wal-Zyr D
- Budesonide and Formoterol-Walgreens Ibuprofen Junior Strength
- Budesonide and Formoterol-Warfarin
- Wakix Tablets-Budesonide and formoterol inhalation
- Wakix Tablets-Budesonide Capsule
- Wakix Tablets-Budesonide eent
- Wakix Tablets-Budesonide ER Tablets
- Wakix Tablets-Budesonide Extended-Release Capsules
- Wakix Tablets-Budesonide Extended-Release Tablets